BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland.
Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial y
Sales of AstraZeneca's COVID-19 vaccine dwindled to almost nothing in the fourth quarter of 2022, contributing to a weaker-than-expected performance for the group.
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved